Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

602
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
602
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

584
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
584
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

450
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
450
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

478
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
478
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

601
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
601
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

481
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
481

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A qualitative study of the impact of the COVID-19 pandemic on healthcare access and service delivery for people living with chronic obstructive pulmonary disease and asthma.

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology·2026
Same author

Diaphragm plication reduces sleep-related obstructive disturbances in surgically selected patients with unilateral diaphragmatic dysfunction: pilot observational data.

Respiratory medicine and research·2026
Same author

New and persistent psychoactive medication use in intensive care unit survivors with COVID-19: a multicentre population-based cohort study.

Canadian journal of anaesthesia = Journal canadien d'anesthesie·2026
Same author

Refining the Definition for "Low Risk" in Pulmonary Arterial Hypertension: Time to Reduce Morbidity and Mortality.

JACC. Heart failure·2026
Same author

Impact of the COVID-19 pandemic on sex-related disparities in cystic fibrosis healthcare utilization and outcomes: A population study.

PloS one·2026
Same author

Promising signalling pathways for the treatment of pulmonary arterial hypertension.

Current opinion in pulmonary medicine·2026
Same journal

Pneumonia Reimagined: Host, Microbe, and the Shifting Landscape of Disease.

Clinics in chest medicine·2026
Same journal

Advocacy in Pneumonia.

Clinics in chest medicine·2026
Same journal

Vaccines Against Pneumonia: Current Updates.

Clinics in chest medicine·2026
Same journal

Non-antibiotic Treatments for Pneumonia: Host-Directed Therapies, Next-Steps and Future Directions.

Clinics in chest medicine·2026
Same journal

Customizing Antibiotic Treatment for Pneumonia: Can We Have a Single Unified Algorithm for All Types of Pneumonia?

Clinics in chest medicine·2026
Same journal

The Role of Complex Digital Interventions to Improve Pneumonia Care.

Clinics in chest medicine·2026
See all related articles

Related Experiment Video

Updated: Jan 25, 2026

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

763

Pulmonary Hypertension and Exercise.

James R Vallerand1, Jason Weatherald2, Pierantonio Laveneziana3

  • 1Undergraduate Medical Education, Cumming School of Medicine, University of Calgary, 3330 Hospital Drive Northwest G702, Calgary, Alberta T2N 4N1, Canada.

Clinics in Chest Medicine
|May 13, 2019
PubMed
Summary
This summary is machine-generated.

Cardiopulmonary exercise testing aids in diagnosing and assessing pulmonary hypertension (PH). Supervised exercise training shows promise for improving quality of life and survival in PH patients.

Keywords:
Cardiopulmonary exercise testingChronic thromboembolic pulmonary hypertensionDyspneaPulmonary arterial hypertensionPulmonary vascular disease

More Related Videos

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
07:10

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease

Published on: August 24, 2019

10.4K
Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

888

Related Experiment Videos

Last Updated: Jan 25, 2026

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

763
Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
07:10

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease

Published on: August 24, 2019

10.4K
Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

888

Area of Science:

  • Cardiology
  • Pulmonology
  • Exercise Physiology

Background:

  • Cardiopulmonary exercise testing (CPET) is valuable for managing patients with pulmonary hypertension (PH).
  • Exercise exacerbates cardiopulmonary issues, aiding in diagnosis, impairment assessment, dyspnea evaluation, and prognosis estimation for PH patients.

Purpose of the Study:

  • To highlight the utility of CPET in pulmonary hypertension management.
  • To discuss the potential benefits and future research directions for supervised exercise training in PH patients.

Main Methods:

  • Review of the role of CPET in diagnosing and assessing PH.
  • Discussion of the safety, feasibility, and potential prognostic benefits of supervised exercise training in PH.
  • Identification of key components for future exercise training interventions.

Main Results:

  • CPET effectively reveals cardiopulmonary decompensations in PH, informing clinical decisions.
  • Supervised exercise training is safe and feasible for PH patients, potentially improving quality of life and survival.
  • Limited clinical trials exist, indicating a need for more research on exercise training's therapeutic effects.

Conclusions:

  • CPET is an essential tool for PH patient evaluation.
  • Supervised exercise training offers a promising, safe, and feasible therapeutic approach for PH.
  • Future research should focus on structured exercise programs, including endurance, strength, and respiratory training, to optimize outcomes in PH.